Patents Examined by Brenda Brumback
-
Patent number: 7341719Abstract: Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells.Type: GrantFiled: January 9, 1998Date of Patent: March 11, 2008Inventor: Peter K. Law
-
Patent number: 7329645Abstract: Disclosed are TGF-? polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.Type: GrantFiled: January 15, 2002Date of Patent: February 12, 2008Assignee: Applied Protein Sciences, LLCInventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
-
Patent number: 7285624Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 3, 2002Date of Patent: October 23, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7282570Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.Type: GrantFiled: August 5, 2002Date of Patent: October 16, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Daniel Tumas, Colin K. Watanabe, William I. Wood
-
Patent number: 7252995Abstract: The present invention relates to a method of generating neurons from stem cells which comprises culturing neurons in a medium and culturing the stem cells in the resultant mixture. The present invention also relates to a medium for culturing stem cells prepared by culturing neurons in a base culture medium.Type: GrantFiled: December 13, 2002Date of Patent: August 7, 2007Inventors: Yu-Show Fu, Henrich Cheng
-
Patent number: 7250495Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: August 16, 2002Date of Patent: July 31, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Jean-Philippe F. Stephan, Colin K. Watanabe, William I. Wood
-
Patent number: 7235637Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: May 10, 2004Date of Patent: June 26, 2007Assignee: Immunex CorporationInventors: John E. Sims, Blair R. Renshaw
-
Patent number: 7232659Abstract: The present invention relates generally to molecular assemblies, more particularly to an assay for the detection of G-protein coupled receptor (GPCR) molecular assemblies and bead-based detection of ligand-GPCR complexes and to methods for identifying compounds as agonists, partial agonists or antagonists of the binding of G-protein coupled receptors to G-protein and for use of these compounds in the treatment of conditions or disease states in a mammalian subject or patient, including humans, where G-protein coupled receptor binding to G-protein is implicated.Type: GrantFiled: February 4, 2004Date of Patent: June 19, 2007Assignee: STC.UNMInventors: Larry A. Sklar, Eric R. Prossnitz, Peter Simons, Anna Waller, Daniel Cimino, Sean Biggs
-
Patent number: 7229790Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.Type: GrantFiled: August 28, 2001Date of Patent: June 12, 2007Assignee: Lexicon Pharmaceuticals, Inc.Inventors: Carl Johan Friddle, Brenda Gerhardt, Yi Hu
-
Patent number: 7226994Abstract: We describe two primordial germ cell-specifically expressed genes, GCR1 (Fragilis) and GCR2 (Stella), as well as their fragments, homologues, variants or derivatives thereof which are markers for primordial germ cells and may be used to identify such cells in cell populations.Type: GrantFiled: August 21, 2003Date of Patent: June 5, 2007Assignee: Cambridge University Technical Services LimitedInventors: Mitinori Saitou, Azim Surani
-
Patent number: 7227000Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 3, 2002Date of Patent: June 5, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7226786Abstract: F gene-deficient virus virions are successfully recovered by using an F gene-deficient Sendai virus genomic cDNA. Further, F gene-deficient infectious viral particles are successfully constructed by using F-expressing cells as helper cells. Also, F gene and HN gene-deficient virus virions are successfully recovered by using a virus genomic cDNA deficient in both F gene and HN gene. Further, F gene and HN gene-deficient infectious viral particles are successfully produced by using F- and HN-expressing cells as helper cells. A virus deficient in F gene and HN gene and having F protein is constructed by using F-expressing cells as helper cells. In addition, M gene-deficient infectious virus particles were produced using helper cells expressing M protein. From cells infected with M gene-deficient viruses, release of virus-like particles was inhibited. Further, a VSV-G pseudo type virus is successfully constructed by using VSV-G-expressing cells.Type: GrantFiled: December 10, 2002Date of Patent: June 5, 2007Assignee: DNAVEC Research Inc.Inventors: Kaio Kitazato, Tsugumine Shu, Hidekazu Kuma, Yasuji Ueda, Makoto Asakawa, Mamoru Hasegawa, Akihiro Iida, Fumino Tokito, Takahiro Hirata, Tsuyoshi Tokusumi, Makoto Inoue, Yumiko Tokusumi
-
Patent number: 7223390Abstract: Cleavage site for the protease furin is inserted between domains of a membrane glycoprotein. Upon cleavage by furin in the trans-Golgi network, the protein is separated into individual membrane-free domain that retains its native conformation. This protocol can be used to produce virus membrane protein domains for structural analysis and for trials as vaccines.Type: GrantFiled: May 7, 2004Date of Patent: May 29, 2007Assignee: Research Development FoundationInventor: Dennis T. Brown
-
Patent number: 7217540Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: July 9, 2004Date of Patent: May 15, 2007Assignee: Immunex CorporationInventors: John E. Sims, Dirk E. Smith, Teresa L. Born
-
Patent number: 7211261Abstract: The invention includes liquid formulations of botulinum toxin that are stable to storage in liquid form at standard refrigerator temperatures for at least 1–2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes.Type: GrantFiled: September 9, 1999Date of Patent: May 1, 2007Assignee: Solstice Neurosciences, Inc.Inventors: Elizabeth Moyer, Pamela Hirtzer
-
Patent number: 7208321Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 22, 2004Date of Patent: April 24, 2007Assignee: Genentech Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7192592Abstract: Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective amount of zvegf4 in combination with a pharmaceutically acceptable delivery vehicle. Also disclosed are methods for promoting proliferation or differentiation of osteoblasts, osteoclasts, chondrocytes, or bone marrow stem cells comprising culturing the cells in an effective amount of zvegf4.Type: GrantFiled: August 3, 2004Date of Patent: March 20, 2007Assignee: ZymoGenetics, Inc.Inventors: Debra G. Gilbertson, Charles E. Hart
-
Patent number: 7189693Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.Type: GrantFiled: December 16, 2002Date of Patent: March 13, 2007Assignee: CuraGen CorporationInventors: Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein
-
Patent number: 7189804Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 3, 2002Date of Patent: March 13, 2007Assignee: Genentech Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7186689Abstract: The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention relates to novel mutants containing only the entire region involved in the formation of finger 2 including the wrist epitope of a BMP with a specific cysteine residue or specific cysteine residues replaced by a different amino acid. The present invention also relates pharmaceutical compositions containing these mutants and to the use of the mutants and pharmaceutical compositions in therapy.Type: GrantFiled: August 21, 2002Date of Patent: March 6, 2007Assignee: The University of ZurichInventor: Franz Weber